Literature DB >> 29134963

The Cochrane Review Conclusion for Hepatitis C DAA Therapies is Wrong.

Paul Y Kwo1, Mitchell L Shiffman2, David E Bernstein3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29134963     DOI： 10.1038/ajg.2017.420

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  35 in total

1.  Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents.

Authors:  Meghan E Sise; Allyson K Bloom; Jessica Wisocky; Ming V Lin; Jenna L Gustafson; Andrew L Lundquist; David Steele; Michael Thiim; Winfred W Williams; Nikroo Hashemi; Arthur Y Kim; Ravi Thadhani; Raymond T Chung
Journal:  Hepatology       Date:  2015-12-11       Impact factor: 17.425

2.  Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.

Authors:  Michael Manns; Didier Samuel; Edward J Gane; David Mutimer; Geoff McCaughan; Maria Buti; Martín Prieto; José Luis Calleja; Markus Peck-Radosavljevic; Beat Müllhaupt; Kosh Agarwal; Peter Angus; Eric M Yoshida; Massimo Colombo; Mario Rizzetto; Hadas Dvory-Sobol; Jill Denning; Sarah Arterburn; Phillip S Pang; Diana Brainard; John G McHutchison; Jean-François Dufour; Hans Van Vlierberghe; Bart van Hoek; Xavier Forns
Journal:  Lancet Infect Dis       Date:  2016-02-18       Impact factor: 25.071

3.  Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy.

Authors:  Jennifer A Flemming; W Ray Kim; Carol L Brosgart; Norah A Terrault
Journal:  Hepatology       Date:  2016-12-24       Impact factor: 17.425

Review 4.  Direct-acting antivirals for chronic hepatitis C.

Authors:  Janus C Jakobsen; Emil Eik Nielsen; Joshua Feinberg; Kiran Kumar Katakam; Kristina Fobian; Goran Hauser; Goran Poropat; Snezana Djurisic; Karl Heinz Weiss; Milica Bjelakovic; Goran Bjelakovic; Sarah Louise Klingenberg; Jian Ping Liu; Dimitrinka Nikolova; Ronald L Koretz; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2017-06-06

5.  Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders.

Authors:  William M Lee; Jules L Dienstag; Karen L Lindsay; Anna S Lok; Herbert L Bonkovsky; Mitchell L Shiffman; Gregory T Everson; Adrian M Di Bisceglie; Timothy R Morgan; Marc G Ghany; Chihiro Morishima; Elizabeth C Wright; James E Everhart
Journal:  Control Clin Trials       Date:  2004-10

6.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

Authors:  Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272

7.  Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients.

Authors:  Paul Feuerstadt; Ari L Bunim; Heriberto Garcia; Jordan J Karlitz; Hatef Massoumi; Amar J Thosani; Andrew Pellecchia; Allan W Wolkoff; Paul J Gaglio; John F Reinus
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

8.  Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.

Authors:  Eric Lawitz; Mark S Sulkowski; Reem Ghalib; Maribel Rodriguez-Torres; Zobair M Younossi; Ana Corregidor; Edwin DeJesus; Brian Pearlman; Mordechai Rabinovitz; Norman Gitlin; Joseph K Lim; Paul J Pockros; John D Scott; Bart Fevery; Tom Lambrecht; Sivi Ouwerkerk-Mahadevan; Katleen Callewaert; William T Symonds; Gaston Picchio; Karen L Lindsay; Maria Beumont; Ira M Jacobson
Journal:  Lancet       Date:  2014-07-28       Impact factor: 79.321

9.  Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study.

Authors:  Luca Saverio Belli; Marina Berenguer; Paolo Angelo Cortesi; Mario Strazzabosco; Susanne-Rasoul Rockenschaub; Silvia Martini; Cristina Morelli; Francesca Donato; Riccardo Volpes; Georges-Philippe Pageaux; Audrey Coilly; Stefano Fagiuoli; Giuliana Amaddeo; Giovanni Perricone; Carmen Vinaixa; Gabriela Berlakovich; Rita Facchetti; Wojciech Polak; Paolo Muiesan; Christophe Duvoux
Journal:  J Hepatol       Date:  2016-05-17       Impact factor: 25.083

Review 10.  Colonoscopy Reduces Colorectal Cancer Incidence and Mortality in Patients With Non-Malignant Findings: A Meta-Analysis.

Authors:  Jun Pan; Lei Xin; Yi-Fei Ma; Liang-Hao Hu; Zhao-Shen Li
Journal:  Am J Gastroenterol       Date:  2016-01-12       Impact factor: 10.864
View more
  3 in total

1.  Risk of De Novo Hepatocellular Carcinoma Following Use of Direct Acting Antiviral Medications for Treatment of Chronic Hepatitis C.

Authors:  Samuel O Antwi; Holly K Van Houten; Lindsey R Sangaralingham; Tushar Patel
Journal:  Cancer Prev Res (Phila)       Date:  2019-08-26

2.  The interleukin 28B gene polymorphism, rs8099917, in patients with chronic hepatitis C and response to the treatment with pegylated interferon and ribavirin.

Authors:  Hamid Kalantari; Bahram Bagherpour; Tahmine Tavakoli; Mahsa Khodadoostan; Seyed Mehdi Hejazi; Alireza Saadatmand
Journal:  J Res Med Sci       Date:  2019-02-25       Impact factor: 1.852

Review 3.  Hepatitis C virus: A critical approach to who really needs treatment.

Authors:  Elias Kouroumalis; Argyro Voumvouraki
Journal:  World J Hepatol       Date:  2022-01-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.